Pfizer, BioNTech end U.S. COVID vaccine trial over low enrollments; Reuters
Source: SeekingAlpha
2026-04-01 12:13:34 ET
More on Pfizer, BioNTech
- Pfizer: Why Wall Street Habitually Overestimates Target Price
- Why Pfizer Remains A Strong Buy In 2026
- Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next Decade
- Belgian court orders Poland, Romania to accept $2.2B of Pfizer COVID shots
- Pfizer is said to close South San Francisco research site
Read the full article on Seeking Alpha
For further details see:
Pfizer, BioNTech end U.S. COVID vaccine trial over low enrollments; Reuters
Pfizer Inc.
NASDAQ: PFE
PFE Trading
0.31% G/L:
$27.085 Last:
7,801,942 Volume:
$27.18 Open:
PFE Latest News
April 14, 2026 09:50:00 am
Investing $8,000 In Each of These 3 Stocks in 2026 Could Generate $1,500 in Annual Dividends
